Statin adherence in coronary outpatients: The relationship between a novel blood test and pharmacy registry data

IF 4.9 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Atherosclerosis Pub Date : 2025-02-18 DOI:10.1016/j.atherosclerosis.2025.119138

Jonas Pivoriunas , Ingrid Engebretsen , Nils Tore Vethe , Oscar Kristiansen , Toril Dammen , Einar Husebye , Morten W. Fagerland , John Munkhaugen , Elise Sverre

{"title":"Statin adherence in coronary outpatients: The relationship between a novel blood test and pharmacy registry data","authors":"Jonas Pivoriunas , Ingrid Engebretsen , Nils Tore Vethe , Oscar Kristiansen , Toril Dammen , Einar Husebye , Morten W. Fagerland , John Munkhaugen , Elise Sverre","doi":"10.1016/j.atherosclerosis.2025.119138","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><div>An accurate and feasible method to assess adherence to statin therapy is needed. We developed a novel blood test to identify reduced statin adherence and compared statin adherence determined by a single blood test to pharmacy registry data.</div></div><div><h3>Methods</h3><div>In a retrospective cohort study of patients prescribed atorvastatin or simvastatin during hospitalization for a coronary heart disease event, a single blood sample was collected median 18 months later. Patients were unaware of the forthcoming statin analyses. Statin adherence was determined by drug concentration measurements using liquid chromatography mass spectrometry and the Norwegian Prescription Database by gaps in statin dispenses.</div></div><div><h3>Results</h3><div>Out of 451 patients, 9 % (n = 39) had reduced adherence (≥2 doses omitted) determined by the blood test. Among those classified as adherent by the blood test, only 0.7 % (n = 3) had a treatment gap ≥90 days during the preceding three months, whereas 28 % (n = 115) during the entire follow-up period (median 5.9 years). Of 39 patients classified with reduced adherence by the blood test, 28 % (n = 11) had treatment gaps ≥90 days during the preceding three months, and 66 % (n = 26) during the entire study period. Patients classified with reduced adherence by the blood test, but not registry data, had numerically more coronary events prior to the index event compared to adherent patients.</div></div><div><h3>Conclusions</h3><div>In coronary outpatients, high adherence to statin treatment measured by a novel blood test aligns with adherence assessed by pharmacy registry. The blood test emerges as a promising tool for enhancing lipid management in clinical practice.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"403 ","pages":"Article 119138"},"PeriodicalIF":4.9000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0021915025000358","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aims

An accurate and feasible method to assess adherence to statin therapy is needed. We developed a novel blood test to identify reduced statin adherence and compared statin adherence determined by a single blood test to pharmacy registry data.

Methods

In a retrospective cohort study of patients prescribed atorvastatin or simvastatin during hospitalization for a coronary heart disease event, a single blood sample was collected median 18 months later. Patients were unaware of the forthcoming statin analyses. Statin adherence was determined by drug concentration measurements using liquid chromatography mass spectrometry and the Norwegian Prescription Database by gaps in statin dispenses.

Results

Out of 451 patients, 9 % (n = 39) had reduced adherence (≥2 doses omitted) determined by the blood test. Among those classified as adherent by the blood test, only 0.7 % (n = 3) had a treatment gap ≥90 days during the preceding three months, whereas 28 % (n = 115) during the entire follow-up period (median 5.9 years). Of 39 patients classified with reduced adherence by the blood test, 28 % (n = 11) had treatment gaps ≥90 days during the preceding three months, and 66 % (n = 26) during the entire study period. Patients classified with reduced adherence by the blood test, but not registry data, had numerically more coronary events prior to the index event compared to adherent patients.

Conclusions

In coronary outpatients, high adherence to statin treatment measured by a novel blood test aligns with adherence assessed by pharmacy registry. The blood test emerges as a promising tool for enhancing lipid management in clinical practice.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Atherosclerosis 医学-外周血管病

CiteScore

9.80

自引率

3.80%

发文量

1269

审稿时长

36 days

期刊介绍： Atherosclerosis has an open access mirror journal Atherosclerosis: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. Atherosclerosis brings together, from all sources, papers concerned with investigation on atherosclerosis, its risk factors and clinical manifestations. Atherosclerosis covers basic and translational, clinical and population research approaches to arterial and vascular biology and disease, as well as their risk factors including: disturbances of lipid and lipoprotein metabolism, diabetes and hypertension, thrombosis, and inflammation. The Editors are interested in original or review papers dealing with the pathogenesis, environmental, genetic and epigenetic basis, diagnosis or treatment of atherosclerosis and related diseases as well as their risk factors.